Two Sigma Advisers’s Kindred Biosciences, Inc. KIN Stock Holding History

Two Sigma Advisers’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-233,000	Closed	-$2.14M	–	2791
2021 Q2	$2.14M	Buy	233,000 +160,400	+221%	+$933K	0.01%	1269
2021 Q1	$361K	Buy	72,600 +56,300	+345%	+$272K	﹤0.01%	2153
2020 Q4	$70K	Buy	+16,300	New	+$66.3K	﹤0.01%	2296

Other funds holding KIN

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Two Sigma Advisers's KIN Position: Q3 2021 in Review

Two Sigma Advisers sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 233,000 shares — an estimated $2.14M sold.

Two Sigma Advisers first reported a position in KIN in Q4 2020 and held it in 3 quarters. The position peaked at $2.14M in Q2 2021. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

Two Sigma Advisers reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
Two Sigma Advisers sold 233,000 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $2.14M.
Two Sigma Advisers first reported a position in Kindred Biosciences, Inc. in Q4 2020 and held it in 3 quarters.
Two Sigma Advisers's Kindred Biosciences, Inc. position peaked at $2.14M in Q2 2021.
1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on Two Sigma Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.